The first LNP delivering an RNAi therapeutic molecule to reach the market was patisiran in 2018—this drug lowers the hepatic levels of transthyretin for the treatment of hereditary transthyretin-induced amyloidosis [101]. The gene discussed is TTR; the disease is amyloidosis.